Verastem, Inc. (VSTM) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Verastem, Inc. is a biopharmaceutical company focused on RAS/MAPK pathway-driven cancers. The quarter was defined by the commercial launch of AVMAPKI FAKZYNJA CO-PACK (avutometinib and defactinib), which received FDA approval on May 8, 2025, for the treatment of adult patients with KRAS mutant recurrent low-grade serous ovarian cancer (LGSOC). The company operates as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $11.2 million | $0 | $13.4 million | $10.0 million |
| Net Loss | $(98.5) million | $(24.0) million | $(176.6) million | $(66.1) million |
| Net Loss Per Share | $(1.35) | $(0.60) | $(2.73) | $(2.11) |
| Cash & Equivalents | $137.7 million | $88.8 million | As of Sept 30, 2025 | |
| Long-Term Debt | $78.1 million | $40.7 million | As of Sept 30, 2025 | |
| Operating Cash Flow (9M) | $(107.6) million | $(79.7) million | Used in operations |
Material Changes vs. Prior Period
- Revenue Generation: The company transitioned from zero product revenue in Q3 2024 to $11.2 million in Q3 2025 following the May 2025 FDA approval and commercial launch of AVMAPKI FAKZYNJA CO-PACK. This contrasts with Q3 2024, which had no product revenue, and 9M 2024, which included a one-time $10.0 million milestone from the Secura agreement.
- Expense Growth: Operating expenses increased significantly. Selling, General, and Administrative (SG&A) expenses rose 71% quarter-over-quarter (QoQ) to $21.0 million, driven by commercial launch costs. Research and Development (R&D) expenses increased 17% QoQ to $29.0 million, primarily due to increased manufacturing and clinical trial costs.
- Debt Restructuring: In January 2025, the company entered a new Note Purchase Agreement for up to $150 million (initially $75 million drawn) and terminated its prior Loan Agreement with Oxford Finance, resulting in a $1.8 million loss on debt extinguishment in the first nine months of 2025.
- Non-Cash Volatility: The net loss was heavily impacted by a $55.9 million expense related to the change in fair value of warrant liabilities in Q3 2025, compared to a $13.5 million gain in Q3 2024. This was driven by an increase in the company's stock price.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for 12 months following the issuance of these financial statements. While the company has $137.7 million in cash, it anticipates continued operating losses and relies on future product revenues, potential milestones, or additional financing to fund operations.
- Clinical Pipeline:
- RAMP 301: Enrollment for the confirmatory Phase 3 trial in LGSOC was completed early in September 2025. An interim analysis recommended a modest increase in enrollment to 29 additional patients, expected to be completed by Q1 2026.
- VS-7375: The company dosed its first patient in the U.S. Phase 1/2a trial for this KRAS G12D inhibitor in June 2025. Data from the partner's trial in China showed promising response rates in pancreatic and lung cancer.
- Regulatory Risks: The filing highlights risks associated with the change in the U.S. presidential administration in January 2025, including potential changes to drug pricing, reimbursement, and FDA enforcement of advertising regulations.
- Commercialization: The company is actively seeking inclusion of AVMAPKI FAKZYNJA CO-PACK in NCCN guidelines for the KRAS wild-type population, with a review scheduled for October 2025.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $137.7 million cash balance against the projected burn rate, given the "substantial doubt" going concern disclosure.
- Warrant Liability Impact: Assess the volatility of the $48.3 million warrant liability and its potential to distort net loss figures in future quarters based on stock price movements.
- Revenue Sustainability: Monitor the trajectory of AVMAPKI FAKZYNJA CO-PACK sales to determine if product revenue can offset the high operating costs associated with the commercial launch and R&D.
- Debt Covenants: Review the terms of the new Note Purchase Agreement, specifically the revenue participation payments (1% of net sales) and the conditions for the potential additional $75 million in funding.
- Clinical Milestones: Track the enrollment and interim data release for the RAMP 301 confirmatory trial, which is critical for full FDA approval and expanded indications.